H Grant Skaggs Jr
Examiner (ID: 16447)
Most Active Art Unit | 3101 |
Art Unit(s) | 3651, 1301, 3615, 3653, 2899, 3101 |
Total Applications | 2062 |
Issued Applications | 1836 |
Pending Applications | 39 |
Abandoned Applications | 187 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 13944703
[patent_doc_number] => 10208107
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-02-19
[patent_title] => Antibodies directed against influenza
[patent_app_type] => utility
[patent_app_number] => 15/083515
[patent_app_country] => US
[patent_app_date] => 2016-03-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 90
[patent_figures_cnt] => 30
[patent_no_of_words] => 29043
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15083515
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/083515 | Antibodies directed against influenza | Mar 28, 2016 | Issued |
Array
(
[id] => 14980653
[patent_doc_number] => 10444234
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-10-15
[patent_title] => Assay for JC virus antibodies
[patent_app_type] => utility
[patent_app_number] => 15/063777
[patent_app_country] => US
[patent_app_date] => 2016-03-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 9
[patent_no_of_words] => 11781
[patent_no_of_claims] => 53
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 92
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15063777
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/063777 | Assay for JC virus antibodies | Mar 7, 2016 | Issued |
Array
(
[id] => 15848211
[patent_doc_number] => 10639366
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-05-05
[patent_title] => Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
[patent_app_type] => utility
[patent_app_number] => 15/553222
[patent_app_country] => US
[patent_app_date] => 2016-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 22
[patent_no_of_words] => 25329
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15553222
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/553222 | Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors | Feb 24, 2016 | Issued |
Array
(
[id] => 14360179
[patent_doc_number] => 10301377
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-05-28
[patent_title] => Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
[patent_app_type] => utility
[patent_app_number] => 15/553466
[patent_app_country] => US
[patent_app_date] => 2016-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 36
[patent_figures_cnt] => 56
[patent_no_of_words] => 61368
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 204
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15553466
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/553466 | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use | Feb 23, 2016 | Issued |
Array
(
[id] => 10988880
[patent_doc_number] => 20160185826
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-06-30
[patent_title] => 'VIRUS-LIKE PARTICLE VACCINES'
[patent_app_type] => utility
[patent_app_number] => 15/015249
[patent_app_country] => US
[patent_app_date] => 2016-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 29
[patent_no_of_words] => 20528
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15015249
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/015249 | VIRUS-LIKE PARTICLE VACCINES | Feb 3, 2016 | Abandoned |
Array
(
[id] => 12247361
[patent_doc_number] => 09920128
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-03-20
[patent_title] => 'Synthetic antiserum for rapid-turnaround therapies'
[patent_app_type] => utility
[patent_app_number] => 15/001349
[patent_app_country] => US
[patent_app_date] => 2016-01-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 6720
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 157
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15001349
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/001349 | Synthetic antiserum for rapid-turnaround therapies | Jan 19, 2016 | Issued |
Array
(
[id] => 15355551
[patent_doc_number] => 10526376
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-01-07
[patent_title] => Virus-like particle with efficient epitope display
[patent_app_type] => utility
[patent_app_number] => 15/542623
[patent_app_country] => US
[patent_app_date] => 2016-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 26
[patent_figures_cnt] => 26
[patent_no_of_words] => 30707
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15542623
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/542623 | Virus-like particle with efficient epitope display | Jan 14, 2016 | Issued |
Array
(
[id] => 12983608
[patent_doc_number] => 20170343530
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-11-30
[patent_title] => LIPID BILAYER-INTEGRATED SPP1 CONNECTOR PROTEIN NANOPORE AND SPP1 CONNECTOR PROTEIN VARIANTS FOR USE AS LIPID BILAYER-INTEGRATED NANOPORE
[patent_app_type] => utility
[patent_app_number] => 15/543821
[patent_app_country] => US
[patent_app_date] => 2016-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26558
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15543821
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/543821 | Lipid bilayer-integrated SPP1 connector protein nanopore and SPP1 connector protein variants for use as lipid bilayer-integrated nanopore | Jan 14, 2016 | Issued |
Array
(
[id] => 12199707
[patent_doc_number] => 09902763
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-02-27
[patent_title] => 'Anti-HPV E7 antibodies'
[patent_app_type] => utility
[patent_app_number] => 14/988981
[patent_app_country] => US
[patent_app_date] => 2016-01-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 21
[patent_no_of_words] => 11035
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14988981
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/988981 | Anti-HPV E7 antibodies | Jan 5, 2016 | Issued |
Array
(
[id] => 13699859
[patent_doc_number] => 20170360884
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-12-21
[patent_title] => METHOD FOR TREATING INFLUENZA A VIRUS INFECTION
[patent_app_type] => utility
[patent_app_number] => 15/537051
[patent_app_country] => US
[patent_app_date] => 2015-12-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5003
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15537051
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/537051 | Method for treating influenza A virus infection | Dec 28, 2015 | Issued |
Array
(
[id] => 13011767
[patent_doc_number] => 10028984
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-07-24
[patent_title] => Clostridium perfringens bacteriophage Clo-PEP-1 and use thereof for inhibiting proliferation of clostridium perfringens
[patent_app_type] => utility
[patent_app_number] => 15/538252
[patent_app_country] => US
[patent_app_date] => 2015-12-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 2
[patent_no_of_words] => 4651
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15538252
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/538252 | Clostridium perfringens bacteriophage Clo-PEP-1 and use thereof for inhibiting proliferation of clostridium perfringens | Dec 27, 2015 | Issued |
Array
(
[id] => 10767870
[patent_doc_number] => 20160114026
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-04-28
[patent_title] => 'PAN-LYSSAVIRUS VACCINES AGAINST RABIES'
[patent_app_type] => utility
[patent_app_number] => 14/978135
[patent_app_country] => US
[patent_app_date] => 2015-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 17031
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14978135
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/978135 | PAN-LYSSAVIRUS VACCINES AGAINST RABIES | Dec 21, 2015 | Abandoned |
Array
(
[id] => 10755015
[patent_doc_number] => 20160101167
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-04-14
[patent_title] => 'Composition of Organic Compounds'
[patent_app_type] => utility
[patent_app_number] => 14/972187
[patent_app_country] => US
[patent_app_date] => 2015-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8095
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14972187
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/972187 | Composition of Organic Compounds | Dec 16, 2015 | Abandoned |
Array
(
[id] => 13699953
[patent_doc_number] => 20170360931
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-12-21
[patent_title] => METHODS AND COMPOSITION FOR NEUTRALIZATION OF INFLUENZA
[patent_app_type] => utility
[patent_app_number] => 15/536857
[patent_app_country] => US
[patent_app_date] => 2015-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21978
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15536857
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/536857 | Methods and composition for neutralization of influenza | Dec 16, 2015 | Issued |
Array
(
[id] => 12029539
[patent_doc_number] => 20170319637
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-11-09
[patent_title] => 'PHAGE THERAPY'
[patent_app_type] => utility
[patent_app_number] => 15/524271
[patent_app_country] => US
[patent_app_date] => 2015-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 8518
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15524271
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/524271 | Phage therapy | Nov 5, 2015 | Issued |
Array
(
[id] => 10996374
[patent_doc_number] => 20160193321
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-07-07
[patent_title] => 'MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS'
[patent_app_type] => utility
[patent_app_number] => 14/933965
[patent_app_country] => US
[patent_app_date] => 2015-11-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 23833
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 17
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14933965
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/933965 | MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS | Nov 4, 2015 | Abandoned |
Array
(
[id] => 12542898
[patent_doc_number] => 10010499
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-07-03
[patent_title] => Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
[patent_app_type] => utility
[patent_app_number] => 14/930831
[patent_app_country] => US
[patent_app_date] => 2015-11-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 5
[patent_no_of_words] => 13535
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 122
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14930831
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/930831 | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus | Nov 2, 2015 | Issued |
Array
(
[id] => 12549147
[patent_doc_number] => 10012594
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-07-03
[patent_title] => Coliphage biosensor
[patent_app_type] => utility
[patent_app_number] => 14/929600
[patent_app_country] => US
[patent_app_date] => 2015-11-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 22
[patent_no_of_words] => 3921
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14929600
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/929600 | Coliphage biosensor | Nov 1, 2015 | Issued |
Array
(
[id] => 15381897
[patent_doc_number] => 10532107
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-01-14
[patent_title] => Modified virus-like particles of CMV
[patent_app_type] => utility
[patent_app_number] => 15/520676
[patent_app_country] => US
[patent_app_date] => 2015-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 25
[patent_no_of_words] => 31796
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 136
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15520676
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/520676 | Modified virus-like particles of CMV | Oct 19, 2015 | Issued |
Array
(
[id] => 12470076
[patent_doc_number] => 09988608
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2018-06-05
[patent_title] => Methods of expanding bacteriophage host-range and bacteriophage produced by the methods
[patent_app_type] => utility
[patent_app_number] => 14/883366
[patent_app_country] => US
[patent_app_date] => 2015-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 43
[patent_no_of_words] => 11597
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 155
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14883366
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/883366 | Methods of expanding bacteriophage host-range and bacteriophage produced by the methods | Oct 13, 2015 | Issued |